4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001628280-25-010672
Chief Executive Officer sold 300,000 shares at an average $17.58 ($5,274,334)
- Chief Executive Officer acquired 300,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-03 | Option exercise 10b5-1 | +166,667 | $7.75 | $1,291,669 | 3,940,469 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-04 | Option exercise 10b5-1 | +133,333 | $7.75 | $1,033,331 | 4,073,802 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-03 | Sale 10b5-1 | −166,667 | $18.03 | $3,005,006 | 3,907,135 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-04 | Sale 10b5-1 | −133,333 | $17.02 | $2,269,328 | 3,773,802 | D |
| Derivatives | |||||||
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-03 | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −166,667 | 185,059 | D | ||
| Anzalone Christopher Richard Chief Executive Officer | 2025-03-03 | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −133,333 | 51,726 | D | ||
| Open-market sales · 300,000 sh · avg $17.58 · $5,274,334 | |||||||
Loading xslF345X05/wk-form4_1741217520.xml…